EBITDA Margin: Earnings before interest, taxes, depreciation and amortization as a portion of total revenue. Calculated as: EBITDA / Total Revenues
Crescent Biopharma, Inc. (CBIO) had EBITDA Margin of -1406.75% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$10.84M |
|
$-153.94M |
|
-- |
|
$10.84M |
|
$163.48M |
|
$-152.63M |
|
$0.69M |
|
$-151.94M |
|
$-151.94M |
|
$-153.94M |
|
$-153.94M |
|
$-153.94M |
|
$-153.94M |
|
$-152.63M |
|
$-152.55M |
|
10.41M |
|
10.41M |
|
$-12.81 |
|
$-12.81 |
|
| Balance Sheet Financials | |
$236.66M |
|
$0.85M |
|
$3.64M |
|
$240.29M |
|
$36.07M |
|
-- |
|
$1.21M |
|
$37.28M |
|
$199.01M |
|
$203.01M |
|
$203.01M |
|
27.56M |
|
| Cash Flow Statement Financials | |
$-71.53M |
|
$-72.92M |
|
$322.98M |
|
$34.77M |
|
$213.30M |
|
$178.53M |
|
$13.30M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.56 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-1407.53% |
|
-1407.53% |
|
|
EBITDA Margin |
-1406.75% |
-1401.16% |
|
-1419.61% |
|
$-72.45M |
|
-- |
|
-- |
|
-- |
|
0.05 |
|
-- |
|
0.60 |
|
605.87 |
|
-77.35% |
|
-75.83% |
|
-64.06% |
|
-75.83% |
|
$7.37 |
|
$-6.96 |
|
$-6.87 |
|